Indeed, in silico analyses of TCGA data revealed a significantly increased expression of ACE2 and of IFN-regulated molecules, such as MHC class I APM components and PD-L1, in COVID-19 patients when compared to their controls, which is in line with the COVID-19 genome databases. This evidence concerns the gene ACE2 and COVID-19.